Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma
The clinical management of metastatic urothelial carcinoma (mUC) is undergoing a major paradigm shift; the integration of immune checkpoint inhibitors (ICIs) and antibody–drug conjugates (ADCs) into the mUC therapeutic strategy has succeeded in improving platinum-based chemotherapy outcomes. Given t...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI AG
2024-03-01
|
| Seri Bilgileri: | Medicina |
| Konular: | |
| Online Erişim: | https://www.mdpi.com/1648-9144/60/4/585 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|